Study title: A randomised controlled trial comparing low molecular weight heparin (reviparin sodium) to standard of practice unfractionated heparin plus a vitamin K antagonist for the treatment of venous thromboembolism in a pediatric patient population.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Cardiovascular Diseases | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: REVIPARIN | |||||
ATC code: B01AB08 | |||||
Document link: Reviparin-CL052.pdf | |||||
Document date: 2011-10-14 | |||||
Study number: CL052 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |